These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 4064465)

  • 1. Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes.
    Raskin P; Rosenstock J; Challis P; Ryder S; Mullane JF; Gonzalez R; Hicks D; Smith T; Dvornik D
    Clin Pharmacol Ther; 1985 Dec; 38(6):625-30. PubMed ID: 4064465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes.
    van Griensven JM; Jusko WJ; Lemkes HH; Kroon R; Verhorst CJ; Chiang ST; Cohen AF
    Clin Pharmacol Ther; 1995 Dec; 58(6):631-40. PubMed ID: 8529328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N; Greselin E; Dubuc J; Dvornik D
    Metabolism; 1985 Oct; 34(10):885-92. PubMed ID: 3930915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolrestat kinetics.
    Hicks DR; Kraml M; Cayen MN; Dubuc J; Ryder S; Dvornik D
    Clin Pharmacol Ther; 1984 Oct; 36(4):493-9. PubMed ID: 6478735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.
    Fruncillo R; Troy S; Parker V; Mayersohn M; Hicks D; Kraml M; Battle M; Chiang S
    Clin Pharmacol Ther; 1996 Jun; 59(6):603-12. PubMed ID: 8681485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients.
    Hamada Y; Kitoh R; Raskin P
    Diabetes; 1991 Oct; 40(10):1233-40. PubMed ID: 1936586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red blood cell sorbitol in diabetic children.
    Ishida Y; Okamoto R; Mino M; Konishi K
    Acta Paediatr Jpn; 1994 Dec; 36(6):642-8. PubMed ID: 7871974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients.
    Ihm SH; Yoo HJ; Park SW; Park CJ
    Metabolism; 1997 Jun; 46(6):634-8. PubMed ID: 9186297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red cell sorbitol: an indicator of diabetic control.
    Malone JI; Knox G; Benford S; Tedesco TA
    Diabetes; 1980 Nov; 29(11):861-4. PubMed ID: 7429027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
    Cunningham JJ; Mearkle PL; Brown RG
    J Am Coll Nutr; 1994 Aug; 13(4):344-50. PubMed ID: 7963139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion.
    McAuliffe AV; Brooks BA; Fisher EJ; Molyneaux LM; Yue DK
    Nephron; 1998 Nov; 80(3):277-84. PubMed ID: 9807036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of two aldose reductase inhibitors upon sorbitol output, D-glucose metabolism and insulin release in islets from normal and hereditarily diabetic rats.
    Flores LE; Gagliardino JJ; Sener A; Malaisse WJ
    Pharmacol Res; 1998 Jun; 37(6):493-6. PubMed ID: 9695123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red blood cell sorbitol lowering effects and tolerance of single doses of AL 1576 (HOE 843) in diabetic patients.
    Averbuch M; Weintraub M; Liao JC; Brazzell RK; Dobbs RE
    J Clin Pharmacol; 1988 Aug; 28(8):757-61. PubMed ID: 3145943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].
    Daniele E; Coco MP
    Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of NaCl, glucose, and aldose reductase inhibitors on cloning efficiency of renal medullary cells.
    Yancey PH; Burg MB; Bagnasco SM
    Am J Physiol; 1990 Jan; 258(1 Pt 1):C156-63. PubMed ID: 2105652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental and clinical studies on the reduction of erythrocyte sorbitol-glucose ratios by ascorbic acid in diabetes mellitus.
    Wang H; Zhang ZB; Wen RR; Chen JW
    Diabetes Res Clin Pract; 1995 Apr; 28(1):1-8. PubMed ID: 7587907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeys.
    Cayen MN; Hicks DR; Ferdinandi ES; Kraml M; Greselin E; Dvornik D
    Drug Metab Dispos; 1985; 13(4):412-9. PubMed ID: 2863103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients].
    Zhang JQ; Mao XM; Zhou YP
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 1993 Dec; 13(12):725-6, 708. PubMed ID: 8136645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.